Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers April 26, 2018
Pharmacy Choice - News - Generic Drugs - April 26, 2018

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 60     Next >>     Go To Page:

4/26/18 - Immunology Biosimilars Market to Make Great Impact in Near Future by 2025: Transparency Market Research Report Added "Immunology Biosimilars Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025"
Albany, NY 04/26/2018 A biosimilar medicine possesses similar pharmacokinetic and mode of action as an original biological medicine that has already been approved for therapeutic use. Biosimilars are made from a living organism such as bacteria and yeast or can also be derived from small molecules such as human insulin, erythropoietin, and mo
4/26/18 - Rep. Matsui Issues Opening Remarks at Health Subcommittee Markup of Opioid Legislation
Doris O. Matsui, D- California, issued the following opening remarks at the House Energy and Commerce subcommittee on Health markup on opioid legislation and the Animal Drug and Animal Generic Drug User Fee Amendments:. "Our Committee has a daunting, yet absolutely essential, task before us today: to make policy changes that address the opioid epi
4/25/18 - Ajay Singh of Slayback Pharma named Ernst and Young's Entrepreneur Of The Year 2018 Award Finalist in New Jersey
Slayback Pharma today announced that CEO, Ajay Singh of Slayback Pharma LLC is named as one of the finalists for Ernst and Young's Entrepreneur Of The Year 2018 Award in the New Jersey region. Ajay Singh was selected as a finalist by a panel of independent judges. In the New Jersey, regional sponsor include PNC Bank, DLA Piper, Morgan Lewis, P
4/25/18 - ANI Pharmaceuticals Announces Approval of Morphine Sulfate Oral Solution
BAUDETTE- ANI Pharmaceuticals, Inc. today announced that it has received approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application for Morphine Sulfate Oral Solution 10 mg/5mL, 20 mg/5mL and 100 mg/5mL. The current annual U.S. market for this product is approximately $17 million, according to Iqvia/IMS Health.
4/25/18 - Citizens for taking action against sale of sub-standard medicines
Citizens of twin cities of Rawalpindi and Islamabad on Tuesday urged the authorities concerned to take strict action against sale of sub-standard and spurious drugs by the medical stores. Ahmad Shah, a citizen said that Drug Regulatory Authority of Pakistan has an important role to play in this regard to ensure fulfilment of all laws by the medical
4/25/18 - Generic Drugs Market Forecast 2018-2028
Visiongain, a research firm, issued the following report:. The generic drugs market is estimated at $257.3 bn in 2017 and is expected to grow at a CAGR of 7.9 percent from 2017 to 2028. The generic drugs market is expected to grow at a CAGR of 7.2 percent in the second half of the forecast period.
4/25/18 - Heritage Pharma Announces Executive Leadership Changes
EAST BRUNSWICK- Heritage Pharmaceuticals Inc., an East Brunswick-based specialty generic pharmaceutical company, today announced that industry veteran William S. Marth has joined the Company as President and Chief Executive Officer, North America and Europe, of the Company's parent, Heritage Pharma Holdings Inc.. Mr. Marth also will be appointed as
4/25/18 - Mylan Adds to Growing Women's Healthcare Portfolio with Launch of Generic for Oral Contraceptive Yaz
HERTFORDSHIRE, England and PITTSBURGH, April 25, 2018/ PRNewswire/ Global pharmaceutical company Mylan N.V. today announced the U.S. launch of Drospirenone and Ethinyl Estradiol Tablets USP, 3 mg/0. 02 mg, a generic version of Bayer's Yaz Tablets. In the U.S., Mylan offers more than 20 generic birth control medicines in multiple dosage forms.
4/25/18 - Pharmaceutical products
Address: Bramfelder Str. 140, Hamburg, 22305, 02.10, NUTS code: DE6, Attn: DZ EM, 02.10. Description: Contract notice: Pharmaceutical products Generic 2018-02 Description: The above-mentioned subject lot is intended to conclude a rebate agreement with a pharmaceutical entrepreneur. Time limit for receipt of tenders or requests to participate: Date:
4/25/18 - Rx Partnership Awarded Grant from the Williamsburg Community Foundation to Support Medication Access Locally at Olde Towne Medical & Dental Center
Recognizing the increasing difficulty uninsured, low-income patients have affording generic medications to treat their chronic conditions, Rx Partnership created a new, innovative program that focuses on dispensing generic medications to patients at Virginia free clinics and health centers.
4/25/18 - Squeezed Mylan axing 500 jobs in West Virginia to `right-size` massive plant [Arab Finance (Egypt)]
The changes those cuts will make are "consistent with discussions we are having with the U.S. Food and Drug Administration and... necessary in order to position the site as best we can for continued operations," the spokesperson added. The company said it`s "committed" to maintaining its U.S. manufacturing footprint and plans to "continue making th
4/24/18 - Argentum and Cosmo Settle Patent Dispute Over UCERIS
Argentum Pharmaceuticals LLC, a generic pharmaceutical company, announced that it has reached a settlement agreement with Cosmo Technologies Limited related to Argentum's inter partes review petition challenging an Orange Book-listed patent for UCERIS . The patent that was being challenged by Argentum is currently the subject of the following..
4/24/18 - Biocon to gain as Pfizer's Herceptin biosimilar delayed further [India Infoline News Service]
USFDA has asked Pfizer to disclose more technical details of its Herceptin biosimilar i.e. Pfizer has said that USFDA s query is not related to manufacturing but related to the technical details. Pfizer also faces a legal challenge of patent infringement from Roche, Herceptin s innovator.
4/24/18 - BIOGEN INC. - 10-Q - Management's Discussion and Analysis of Financial Condition and Results of Operations
The following discussion should be read in conjunction with our unaudited condensed consolidated financial statements and accompanying notes beginning on page 5 of this quarterly report on Form 10- Q and our audited consolidated financial statements and related notes included in our Annual Report on Form 10- K for the year ended December 31, 2017.
4/24/18 - Drug firms spend huge sums to drive growth [Tehran Times (Iran)]
On April 10 Vingroup said in its website that it has established Vinfa JSC and would spend VN2.2 trillion to set up a 10 hectare drug manufacturing and research centre in Gia Bnh District in the northern province of Bc Ninh. It will collaborate with partners from the US, Europe and Australia to acquire know-how and technology and import drugs to di
4/24/18 - Endo Receives Paragraph IV Notification on Vasostrict
DUBLIN- Endo International plc today announced that its subsidiaries, Par Pharmaceutical, Inc. and Par Sterile Products, LLC, have received a Notice Letter dated April 16, 2018 advising that Eagle Pharmaceuticals, Inc. has submitted an Abbreviated New Drug Application to the U.S. Food and Drug Administration seeking approval from the FDA to manufac
4/24/18 - Oral Biologics Delivery Could Be The Key For Biosimilars To Gain Market Share From Blockbuster Drugs
SANTA CLARA, Calif. and SAN JOSE, Calif., April 24, 2018/ PRNewswire/ Frost& Sullivan, the global research and consulting organization, and Rani Therapeutics, the pioneer in oral biologics, today announced the results of a research study that points the way for biosimilar companies to take market share from blockbuster drugs, and for pharmaceutic
4/24/18 - Pharmaceutical Packaging Equipment Market Analysis and Forecast by 2025: The global pharmaceutical packaging equipment market is estimated to witness a healthy growth in the coming years. Some of the key factors encouraging the growth of the market i
San Francisco, CA 04/23/2018 Packaging of pharmaceutical products is considered to be a very crucial element for the pharmaceutical industry because such packaging ensures the quality and safety of drugs that it contains. As such, it is estimated that there will be a constant requirement for pharmaceutical packaging equipment in the industry
4/24/18 - Scott Cunning to Speak at Financial Times Summit
Haynes and Boone, a law firm, issued the following news release:. Haynes and Boone, LLP Partner Scott Cunning, the administrative partner for the firm's Washington, D.C., office, will speak May 10 at the Financial Times U.S. Healthcare& Life Sciences Summit in New York City. A member of Haynes and Boone's Biosimilars Practice Group, Cunning will be
4/24/18 - Supply Of Infliximab Or Biosimilar [TendersInfo (India)]
Tenders are invited for To Appoint A Single Provider For The Provision, Supply, Support And Delivery Of Infliximab Or Infliximab Biosimilar To Patients In Our Lady~ S Children~ S Hospital Crumlin. It Is Envisaged That Infliximab-Nave Patients In Olchc Will Receive The Tendered Product Initially With A View To Switch All Existing Patients Within 6 M
4/23/18 - ACETO CORP FILES (8-K) Disclosing Other Events
In connection with the DOJ's ongoing investigation into marketing and pricing practices throughout the generic pharmaceutical industry, Aceto Corporation received a subpoena from the Antitrust Division of the U.S. Department of Justice. The Company is one of many operating companies in the generic pharmaceutical industry to receive a subpoena from
4/23/18 - Aceto Corporation (NASDAQ:ACET) Files An 8-K Other Events
Aceto Corporation (NASDAQ:ACET) Files An 8-K Other EventsItem 8.01 Other Events In connection with the DOJ's ongoing investigation into marketing and pricing practices throughout the generic pharmaceutical industry, Aceto Corporation (the Company) received a subpoena from the Antitrust Division of the U.S. Department of Justice (the DOJ
4/23/18 - Amerigen and Dipharma Announce U.S. FDA Approval for Generic Miglustat 100 mg Capsules
LYNDHURST, N.J. and CHIASSO, Switzerland, April 23rd, 2018/ PRNewswire/ Amerigen Pharmaceuticals Limited and Dipharma S.A. today announced that Amerigen's Abbreviated New Drug Application for Miglustat 100 mg capsules has received final approval from the U.S. Food and Drug Administration. Miglustat active ingredient is supplied to Amerigen by Dip
4/23/18 - Cipher Pharmaceuticals Provides Corporate Update and Preliminary Q1 2018 Revenue Results
-Cipher Pharmaceuticals Inc. today provided a strategic and operational update and preliminary revenue results for the three months ended March 31, 2018. Canadian Commercial Operation In Canada, Cipher is focused on organic growth of its currently marketed products, as well as the in-licensing and/or acquisition of new products that are highly nove
4/23/18 - Endo Receives Paragraph IV Notification on Vasostrict
DUBLIN- Endo International plc today announced that its subsidiaries, Par Pharmaceutical, Inc. and Par Sterile Products, LLC, have received a Notice Letter dated April 16, 2018 advising that Eagle Pharmaceuticals, Inc. has submitted an Abbreviated New Drug Application to the U.S. Food and Drug Administration seeking approval from the FDA to manufac
Articles(s): 1 - 25 of 60     Next >>     Go To Page:


© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415